Genitourinary Cancer
News
Lower Dose Keeps Cabozantinib Alive in Prostate Cancer
Major Finding: A bone scan response was achieved in 67% of patients receiving cabozantinib at 40 mg and at 100 mg daily.Data Source: Researchers...
News
Cabozantinib Hits Metastatic Kidney Cancer
News
Prostate Cancer Therapies: From Fast-Track to Graveyard-Bound
Major Finding: Radium-223 was the big winner, with a 30.5% reduction in the risk of death compared with placebo in men with CRPC and bone...
News
OGX-427 Takes Aim at Novel Target in Prostate Cancer
Major Finding: At 12 weeks, 71% of patients on OGX-427 plus prednisone were progression free, compared with 40% on prednisone alone.Data Source:...
News
Abiraterone Blocks Chemo-Naive Prostate Cancer
Major Finding: Radiographic progression-free survival was a median of 8.3 months in the control arm, but had not been reached in the abiraterone...
News
Tivozanib Surpasses Sorafenib in Stalling Kidney Cancer
Major Finding: Median progression-free survival for 260 patients with advanced renal cell carcinoma randomized to tivozanib was 11.9 months in an...
News
Anti-PD-1 Agent Active in Metastatic Kidney Cancer
Major Finding: Nine of 33 patients (27%) with metastatic renal cell carcinoma had clinical responses to an anti-PD-1 monoclonal antibody,...
News
Duloxetine Eases Pain of Chemo-Induced Neuropathy
Major Finding: A pain reduction of 30% or more was seen in 33% of patients on duloxetine vs. 17% on placebo.Data Source: Investigators conducted a...
Conference Coverage
Intermittent Hormone Therapy Shortens Prostate Cancer Survival
Major Finding: Men with minimal disease lived a median of 5.2 years if randomized to intermittent androgen deprivation vs.
News
Immunotherapy Targeting PD-1 Pathway Strikes Chord Across Cancers
Major Finding: Objective responses rates were 28% in melanoma, 27% in kidney cancer, and 18% in NSCLC, with stable disease in 6%, 27%, and 7%.Data...
News
Patients Pick Pazopanib Over Sunitinib for Metastatic RCC
Major Finding: 70% of patients with metastatic renal cell carcinoma expressed a preference for pazopanib, compared with 22% for sunitinib (P less...